Failure of standard contemporary ST-elevation myocardial infarction electrocardiogram criteria to reliably identify acute occlusion of the left anterior descending coronary artery

  • Powerful Medical
  • July 28, 2025
  • 3 min to read
European Heart Journal Acute Cardiovascular Care article title page on STEMI criteria missing LAD occlusion

Overview

ST-elevation (STE) criteria on the electrocardiogram (ECG) are poorly sensitive for acute coronary occlusion myocardial infarction (ACOMI or OMI). This study evaluates the sensitivity of STE criteria on serial ECGs for total left anterior descending (LAD) coronary artery occlusion. We compared STE criteria with expert interpretation and a validated artificial intelligence (AI) ECG model for diagnosing LAD OMI.

Key findings

  • ST-elevation criteria are poorly sensitive for total LAD occlusion.
  • Evaluated across serial ECGs for LAD occlusion MI.
  • Compared STEMI criteria vs expert reading and a validated AI model.

Published in: European Heart Journal. Acute Cardiovascular Care
Published on: 28 July 2025

Background

The Queen of Hearts (QoH) ECG artificial intelligence (AI) model (PMcardio, Bratislava, Slovakia) has demonstrated improved sensitivity for detecting occlusion myocardial infarction (OMI) compared with STEMI criteria, but further validation in all-comer cohorts is needed. We aimed to evaluate QoH’s diagnostic performance for OMI detection in chest pain patients at Swedish emergency departments (EDs) and compare its accuracy to STEMI criteria.

Methods

This is a retrospective sub-study of the DOMI-ARIGATO case-control study of OMI (808 patients, 265 with OMI). All cases of total (TIMI-0 flow) LAD occlusion were assessed for STE criteria. An OMI ECG expert blindly interpreted all serial ECGs. An AI model (PMCardio Queen of Hearts) was applied to the first available 12-lead ECG.

Results

Among the 53 cases of acute LAD OMI with TIMI-0 flow, 20 (38%) did not meet STE myocardial infarction (STEMI) criteria on any pre-angiography ECG; 16/ 20 had at least two ECGs before angiography. Both the expert and AI model had 100% sensitivity for diagnosing LAD OMI on the first ECG in these 20 cases. Door-to-balloon time (DBT) was significantly shorter for those meeting STEMI criteria. Infarct size, measured by ejection fraction and peak troponin, did not differ between cases with and without STEMI criteria.

Conclusion

The STEMI criteria missed 38% of acute total LAD occlusions on all serial ECGs. Both expert interpretation and the AI model demonstrated 100% sensitivity on the first ECG for all cases. Despite the lack of STEMI criteria, these cases had similar infarct sizes but were associated with longer DBTs.

Study flowchart narrowing 808 patients to 53 LAD OMI cases beside PMcardio ECG flagging hyperacute T-waves in V2-V4

Authors: Harvey Pendell Meyers, Scott W. Sharkey, Robert Herman, José Nunes de Alencar, Gautam R. Shroff, Willy H. Frick, and Stephen W. Smith

Share this article

  • Share on Facebook
  • Share on X
  • Share on Linkedin
  • Share via e-mail
  • Copy the link
About PMcardio logo

About PMcardio

PMcardio is the market leader in AI-powered diagnostics, addressing the world’s leading cause of death – cardiovascular diseases. The innovative clinical assistant empowers healthcare professionals to detect up to 40 cardiovascular diseases. In the form of a smartphone application, the certified Class IIb medical device interprets any 12-lead ECG image in under 5 seconds to provide accurate diagnoses and individualized treatment recommendations tailored to each patient.

About Product

About Powerful Medical  logo

About Powerful Medical

Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

About Us